相关实验视频

Updated: Jul 8, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

变异型与 cis型:对因IDH2突变引起的enasidenib耐药性的计算研究

Erik Lindahl1, Erik Arvidsson2, Ran Friedman1

  • 1Department of Chemistry and Biomedical Sciences, Linnaeus University, SE-391 82 Kalmar, Sweden. ran.friedman@lnu.se.

Physical chemistry chemical physics : PCCP
|July 2, 2024
PubMed
概括

异酸脱酶2 (IDH2) 的二次突变导致对癌症药物enasidenib的耐药性. 分子模拟显示,这种耐药性突变在存在于不同的酶单体上时会削弱药物结合.

更多相关视频

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.6K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...